BVNRY
Price
$12.31
Change
+$0.07 (+0.57%)
Updated
Sep 5 closing price
Capitalization
2.88B
DMAC
Price
$6.13
Change
+$0.76 (+14.15%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
317.37M
61 days until earnings call
Interact to see
Advertisement

BVNRY vs DMAC

Header iconBVNRY vs DMAC Comparison
Open Charts BVNRY vs DMACBanner chart's image
Bavarian Nordic A/S
Price$12.31
Change+$0.07 (+0.57%)
Volume$4.87K
Capitalization2.88B
DiaMedica Therapeutics
Price$6.13
Change+$0.76 (+14.15%)
Volume$15.69K
Capitalization317.37M
BVNRY vs DMAC Comparison Chart in %
Loading...
BVNRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BVNRY vs. DMAC commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BVNRY is a Hold and DMAC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (BVNRY: $12.24 vs. DMAC: $5.37)
Brand notoriety: BVNRY and DMAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BVNRY: 49% vs. DMAC: 167%
Market capitalization -- BVNRY: $2.88B vs. DMAC: $317.37M
BVNRY [@Biotechnology] is valued at $2.88B. DMAC’s [@Biotechnology] market capitalization is $317.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BVNRY’s FA Score shows that 0 FA rating(s) are green whileDMAC’s FA Score has 0 green FA rating(s).

  • BVNRY’s FA Score: 0 green, 5 red.
  • DMAC’s FA Score: 0 green, 5 red.
According to our system of comparison, BVNRY is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BVNRY’s TA Score shows that 4 TA indicator(s) are bullish while DMAC’s TA Score has 4 bullish TA indicator(s).

  • BVNRY’s TA Score: 4 bullish, 4 bearish.
  • DMAC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both BVNRY and DMAC are a good buy in the short-term.

Price Growth

BVNRY (@Biotechnology) experienced а -0.69% price change this week, while DMAC (@Biotechnology) price change was -8.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.44%. For the same industry, the average monthly price growth was +9.90%, and the average quarterly price growth was +31.78%.

Reported Earning Dates

DMAC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BVNRY($2.88B) has a higher market cap than DMAC($317M). BVNRY YTD gains are higher at: 41.391 vs. DMAC (-1.105). BVNRY has higher annual earnings (EBITDA): 2.01B vs. DMAC (-31.42M). BVNRY has more cash in the bank: 1.24B vs. DMAC (30M). DMAC has less debt than BVNRY: DMAC (292K) vs BVNRY (117M). BVNRY has higher revenues than DMAC: BVNRY (6.23B) vs DMAC (0).
BVNRYDMACBVNRY / DMAC
Capitalization2.88B317M909%
EBITDA2.01B-31.42M-6,404%
Gain YTD41.391-1.105-3,746%
P/E Ratio13.13N/A-
Revenue6.23B0-
Total Cash1.24B30M4,120%
Total Debt117M292K40,068%
FUNDAMENTALS RATINGS
BVNRY vs DMAC: Fundamental Ratings
BVNRY
DMAC
OUTLOOK RATING
1..100
7777
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
66
Overvalued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
6298
PRICE GROWTH RATING
1..100
4342
P/E GROWTH RATING
1..100
94100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BVNRY's Valuation (45) in the null industry is in the same range as DMAC (66) in the Biotechnology industry. This means that BVNRY’s stock grew similarly to DMAC’s over the last 12 months.

BVNRY's Profit vs Risk Rating (83) in the null industry is in the same range as DMAC (100) in the Biotechnology industry. This means that BVNRY’s stock grew similarly to DMAC’s over the last 12 months.

BVNRY's SMR Rating (62) in the null industry is somewhat better than the same rating for DMAC (98) in the Biotechnology industry. This means that BVNRY’s stock grew somewhat faster than DMAC’s over the last 12 months.

DMAC's Price Growth Rating (42) in the Biotechnology industry is in the same range as BVNRY (43) in the null industry. This means that DMAC’s stock grew similarly to BVNRY’s over the last 12 months.

BVNRY's P/E Growth Rating (94) in the null industry is in the same range as DMAC (100) in the Biotechnology industry. This means that BVNRY’s stock grew similarly to DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BVNRYDMAC
RSI
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
59%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 17 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
BVNRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIVMX13.23N/A
N/A
Fidelity Advisor International Value A
TWCUX100.13N/A
N/A
American Century Ultra® Inv
MARFX24.11N/A
N/A
BlackRock Mid-Cap Value Institutional
ALSRX16.83N/A
N/A
Alger Small Cap Growth Institutional I
NOLCX32.32N/A
N/A
Northern Large Cap Core

BVNRY and

Correlation & Price change

A.I.dvisor tells us that BVNRY and GOVX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BVNRY and GOVX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BVNRY
1D Price
Change %
BVNRY100%
+0.57%
GOVX - BVNRY
28%
Poorly correlated
-5.52%
CRMD - BVNRY
24%
Poorly correlated
-3.13%
VRAX - BVNRY
23%
Poorly correlated
-6.87%
DMAC - BVNRY
22%
Poorly correlated
+14.34%
IPHA - BVNRY
21%
Poorly correlated
-2.20%
More

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+1.32%
WHWK - DMAC
47%
Loosely correlated
N/A
ARCT - DMAC
38%
Loosely correlated
-2.50%
HUMA - DMAC
35%
Loosely correlated
N/A
LQDA - DMAC
32%
Poorly correlated
-1.30%
EDIT - DMAC
31%
Poorly correlated
+0.80%
More